Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,270.35 -7.16 (-0.14%) Dow
38,439.96 -246.36 (-0.64%) Nasdaq
16,798.12 +63.10 (+0.38%) Bitcoin USD
69,137.30 +1,100.03 (+1.62%) CMC Crypto 200
1,486.93 +19.00 (+1.29%)
OLMA Jun 2024 7.500 put
| Previous close | 0.3000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 7.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
GlobeNewswireOlema Oncology to Participate in Upcoming Investor Conferences in June
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024, at 2:00 p.m. ET Location: Marriott Marquis in New York, NY
Simply Wall St.Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWI
